C93.3
Juvenile myelomonocytic leukemia
Clinical Classification Guidelines
Medical Intelligence & Overview
Juvenile myelomonocytic leukemia (JMML) is a rare type of blood cancer that primarily affects young children. It falls under the category of myelodysplastic/myeloproliferative diseases in the International Classification of Diseases, Tenth Revision (ICD-10), with the specific code C93.3. JMML is characterized by the overproduction of myelomonocytic cells, which are a type of white blood cell involved in immune response. This disease can be aggressive, requiring prompt and specialized treatment. Although it is rare, understanding the basics of JMML can help caregivers and families better navigate diagnosis and management options.
Causes & Symptoms
Clinical Causes: Genetic mutations: JMML is often linked to abnormalities in genes that regulate blood cell production, such as mutations in PTPN11, NRAS, KRAS, or NF1. Congenital conditions: Children with certain genetic syndromes, such as neurofibromatosis type 1, Noonan syndrome, or Costello syndrome, have an increased risk of developing JMML. Family history: A family history of blood disorders or genetic conditions related to blood cell regulation may also be associated.
Key Symptoms: Persistent fever Frequent infections due to immune system impairment Anemia symptoms such as fatigue, pallor, or shortness of breath Enlarged spleen (splenomegaly) or liver (hepatomegaly) Easy bruising or bleeding tendencies Weight loss or failure to thrive in young children Unusual bleeding or petechiae (small red or purple spots on the skin)
Diagnostic & Treatment
Diagnosis Path: Diagnosing JMML involves a combination of blood tests, bone marrow examination, and genetic studies. Blood tests may show elevated white blood cell counts, low hemoglobin levels, and abnormal platelet counts. Bone marrow biopsies typically reveal increased myelomonocytic cells with morphological abnormalities. Genetic testing helps identify specific mutations associated with the disease, which can also provide prognostic information. Imaging studies like ultrasound or CT scans are used to assess organ enlargement, particularly of the spleen and liver. Early diagnosis is critical for initiating appropriate treatment and improving outcomes.
Treatment Protocols: Treatment options for JMML often involve chemotherapy to control the proliferation of abnormal cells. In many cases, stem cell (bone marrow) transplantation is recommended as a potential cure, especially in young children. Supportive care measures such as antibiotics for infections, transfusions for anemia or bleeding, and close monitoring of blood counts are essential components of management. The choice of therapy depends on the patient's age, overall health, genetic findings, and disease severity. Ongoing clinical trials and research are exploring targeted therapies that may improve long-term survival and reduce treatment-related side effects.
Clinical Advice & FAQs
Billing Guidance
Is C93.3 a billable ICD-10 code?
Yes, C93.3 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C93.3?
Clinical documentation must specify the nature of Juvenile myelomonocytic leukemia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference